Phase 1 Trial of SHY-ONC6, a Proteasome-Modulating Therapy in Solid Tumors (Including mCRPC)

SHY-ONC6 is now entering a Phase 1 first-in-human clinical study in patients with advanced or metastatic solid tumors. The trial is open-label and multicenter, and its main goals are to assess safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in people whose disease has progressed on standard therapy or who cannot tolerate it.
SHY-ONC6 attacks the proteasome in a way that is different from older agents. For prostate cancer, that matters because proteasome biology has long been linked to tumor growth, survival signaling, and resistance to therapy, even though earlier clinical attempts with proteasome inhibitors produced mixed results.

Cancer cells rely on a tightly regulated protein quality-control system to manage stress, control cell division, and avoid apoptosis. SHY-ONC6 is reported to target a different part of the proteasome pathway than drugs such as bortezomib, carfilzomib, and ixazomib, so it may produce a distinct antitumor effect.

SHY-ONC6 is interesting because it may disrupt proteasome function differently from bortezomib, which raises the possibility that it could address some of the weaknesses seen with earlier proteasome-based approaches in prostate cancer. That idea is biologically plausible because prostate tumors can depend on ubiquitin-proteasome signaling in ways that remain therapeutically relevant, including in PTEN-deleted mCRPC, where a bortezomib study is currently being explored.

Clinical trial.